Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures
Arie Belldegrun didn’t just co-found a new biotech with $300 million in financing. He also is taking the wraps off a new venture fund with $295 million to invest in what he and his partners hope will be the next-gen biotech companies to watch.
The new fund is called Vida Ventures, based in Boston, and one of its first investments went to Belldegrun’s latest CAR-T creation, Allogene. Homology Medicines, Praxis Precision Medicines and Pionyr Immunotherapeutics are also in the portfolio after getting started last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.